---
title: "Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Diagnosis"
description: "Formulary evidence on Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Diagnosis. Topics: Liver biopsy: reference standard for grading and staging, AASLD 2023 practice guidance; Liver biopsy: required for a definite diagnosis of steatohepatitis, EASL-EASD-EASO 2024 guideline; Liver biopsy: only reliable means to diagnose NASH, AGA clinical care pathway; Liver biopsy: reserved to the specialist, ADA Standards of Care 2026; 18 further topics. 22 evidence topics quoted from 13 sources."
canonical: "https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/product-information-and-disease-description/diagnosis"
published: "2026-11-18T22:34:49-05:00"
modified: "2026-11-18T22:34:49-05:00"
---

# Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Diagnosis

<a id="heading-2.2.1.5"></a>

## 2.2.1.5 Diagnosis

<a id="topic-2.2.1.5-1"></a>

### Liver biopsy: reference standard for grading and staging, AASLD 2023 practice guidance

> “Although liver biopsy assessment remains the reference standard for the grading and staging of NASH, it has important limitations related to risk, cost, and resource utilization. Therefore, liver biopsies for grading and staging of NASH are not consistently performed in clinical practice and should be reserved for specific clinical scenarios (Figure 2).”
> “Liver biopsy should be considered when NITs suggest significant fibrosis (≥ F2), especially if additional evaluation suggests the presence of “at-risk” NASH (eg, using FAST, MEFIB, MAST, or cT1), NIT assessment is indeterminate, aminotransferases are persistently elevated (> 6 mo), or additional/alternate diagnoses are suspected.”

Source: [Rinella et al. (2023a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10735173/)

<a id="topic-2.2.1.5-2"></a>

### Liver biopsy: required for a definite diagnosis of steatohepatitis, EASL-EASD-EASO 2024 guideline

> “In most cases, liver biopsy is not required for clinical management of individuals with MASLD; however, liver biopsy is still required for the definite diagnosis of steatohepatitis and can help to rule out alternative causes of liver disease (LoE 1, strong consensus).”
> “None of these non-invasive methods can assess relevant microscopic features of MASLD such as ballooning or lobular inflammation (LoE 2, strong consensus).”

Source: [European Association for the Study of the Liver (2024)](https://www.journal-of-hepatology.eu/article/S0168-8278%2824%2900329-5/fulltext)

<a id="topic-2.2.1.5-3"></a>

### Liver biopsy: only reliable means to diagnose NASH, AGA clinical care pathway

> “A liver biopsy is currently the only reliable means to diagnose NASH and is the reference standard for fibrosis staging. However, liver biopsy may not be feasible to obtain in a significant number of patients.”

Source: [Kanwal et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8819923/)

<a id="topic-2.2.1.5-4"></a>

### Liver biopsy: reserved to the specialist, ADA Standards of Care 2026

> “While liver biopsy remains the gold standard for the diagnosis of MASH, its indication is reserved to the discretion of the specialist within an interprofessional team approach due to high costs and potential for morbidity associated with this procedure.”

Source: [American Diabetes Association Professional Practice Committee (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12690184/)

<a id="topic-2.2.1.5-5"></a>

### Primary risk assessment with FIB-4: thresholds, AASLD 2023 practice guidance

> “When the fibrosis-4 index (FIB-4) is <1.3, patients can be followed in the primary care setting and reassessed periodically.”
> “In patients older than age 65, a FIB-4 cutoff of > 2.0 should be used. FIB-4 has low accuracy in those under age 35; thus, secondary assessment should be considered in those <35 with increased metabolic risk or elevated liver chemistries.”
> “In patients with FIB4 ≥ 1.3, a secondary assessment should be done [preferentially vibration-controlled elastography (VCTE) or Enhanced Liver Fibrosis (ELF) initially] or the patient referred for further risk stratification (if being seen in a nongastroenterology/hepatology setting). Direct referral to gastroenterology/hepatology should be considered in those with aminotransferases persistently (> 6 mo) above normal to exclude other causes of liver disease or when FIB4 > 2.67 due to the increased risk of clinically significant fibrosis.”
> “In addition, a change in FIB-4 status category from low risk (< 1.3) to intermediate risk (1.3–2.67) to high risk (> 2.67) may be used to assess clinical progression.”

Source: [Rinella et al. (2023a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10735173/)

<a id="topic-2.2.1.5-6"></a>

### Primary risk assessment with FIB-4: thresholds and false negatives, EASL-EASD-EASO 2024 guideline

> “If FIB-4 is below 1.3, these individuals can be assumed to be at low risk of advanced fibrosis and may be re-assessed every 1-3 years. However, despite the high negative predictive value, clinicians should recognise that FIB-4 will miss around 10% of individuals with advanced fibrosis, and it has not been formally demonstrated that repeating FIB-4 over time is effective in picking up the remaining individuals.”
> “If FIB-4 is >1.3 (or >2.0 in individuals aged >65), the risk for advanced fibrosis is increased.”
> “One option is that individuals proceed to liver elastography (e.g. VCTE) as a second step to clarify the stage of fibrosis; this option is particularly suggested in individuals with FIB-4 values close to 2.67 or in high-risk conditions.”

Source: [European Association for the Study of the Liver (2024)](https://www.journal-of-hepatology.eu/article/S0168-8278%2824%2900329-5/fulltext)

<a id="topic-2.2.1.5-7"></a>

### Primary risk assessment with FIB-4: thresholds, AGA clinical care pathway

> “Previous studies have shown that FIB-4 score <1.3 (<2.0 in those older than 65 years) can reliably exclude advanced fibrosis in patients with NAFLD, with a negative predictive value of ≥90%.”
> “Patients with FIB-4 score >2.67 are at high risk for advanced fibrosis,”
> “The remaining 30%-40% of patients with an FIB-4 test would likely have values in the indeterminate range (ie, 1.3–2.67).”

Source: [Kanwal et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8819923/)

<a id="topic-2.2.1.5-8"></a>

### Screening with FIB-4 in type 2 diabetes or prediabetes: ADA Standards of Care 2026

> “4.22a Screen adults with type 2 diabetes or with prediabetes, particularly those with obesity or other cardiometabolic risk factors or established cardiovascular disease, for their risk of having or developing cirrhosis related to metabolic dysfunction–associated steatohepatitis (MASH) using a calculated fibrosis-4 index (FIB-4)”
> “4.23 Adults with type 2 diabetes or prediabetes with a FIB-4 ≥ 1.3 should have additional risk stratification by liver stiffness measurement with transient elastography, or, if unavailable, the enhanced liver fibrosis (ELF) test. B”
> “A value of <1.3 is considered low risk of having advanced fibrosis (F3–F4) and for developing adverse liver outcomes, while ≥1.3 is considered as having a higher probability of at-risk MASH clinically significant fibrosis (≥F2) and increased risk of adverse liver outcomes. A value of >2.67 confers a high risk of having advanced fibrosis (F3–F4), and referral to the liver specialist is warranted without additional testing.”
> “In individuals with diabetes ≥65 years of age, higher cutoffs for FIB-4 have been recommended (1.9–2.0 rather than ≥1.3)”

Source: [American Diabetes Association Professional Practice Committee (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12690184/)

<a id="topic-2.2.1.5-9"></a>

### Aminotransferases: frequently normal in clinically significant fibrosis

> “Aminotransferase levels are frequently normal in patients with advanced liver disease due to NASH and should not be used in isolation to exclude the presence of NASH with clinically significant fibrosis”

Source: [Rinella et al. (2023a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10735173/)

> “A screening strategy relying on elevated plasma aminotransferases >40 units/L would miss most individuals with MASH in these settings, as at-risk MASH with clinically significant fibrosis (≥F2) is frequently observed with plasma aminotransferases below the commonly used cutoff of 40 units/L”

Source: [American Diabetes Association Professional Practice Committee (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12690184/)

<a id="topic-2.2.1.5-10"></a>

### Vibration-controlled transient elastography: liver stiffness thresholds, AASLD 2023 practice guidance

> “A recent meta-analysis suggested that a VCTE-derived liver stiffness measurement (LSM) <8 kPa can be used to rule out advanced fibrosis, especially if used sequentially after FIB-4.”
> “LSMs by VCTE between 8 and 12 kPa may be associated with fibrotic NASH, and LSM > 12 kPa is associated with a high likelihood of advanced fibrosis, although the positive predictive value is low (range: 0.34–0.71).”
> “In identifying patients with cirrhosis, a sequential approach with a FIB-4 > 3.48 and LSM by VCTE ≥ 20 kPa had a specificity of 90%.”

Source: [Rinella et al. (2023a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10735173/)

<a id="topic-2.2.1.5-11"></a>

### Vibration-controlled transient elastography: liver stiffness thresholds, AGA clinical care pathway

> “In a study of 450 consecutive adults who underwent liver biopsy and FibroScan for suspected NAFLD at 7 centers, the Youden cutoff value for F≥F2 was 8.2 kPa.”
> “A value of >12.1 kPa on VCTE indicates that clinically significant fibrosis is likely, with positive predictive values of 76% and 88% in patients seen in diabetes and hepatology clinic populations, respectively, although the positive predictive value can be low in primary care populations.”
> “We recommend that patients with discordant or indeterminate LSM results (ie, 8.0–12.0 kPa) in primary care and endocrine clinics be referred to hepatology where, like high-risk patients, they might need to undergo either a liver biopsy or MRE for further diagnostic evaluation.”

Source: [Kanwal et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8819923/)

<a id="topic-2.2.1.5-12"></a>

### Vibration-controlled transient elastography and ELF: thresholds in type 2 diabetes or prediabetes, ADA Standards of Care 2026

> “An LSM value of <8.0 kPa has a good negative predictive value to exclude advanced fibrosis (≥F3–F4)”
> “If the LSM is ≥8.0 kPa, the risk for advanced fibrosis (≥F3-F4) is higher and such individuals should be referred to the hepatologist”
> “Individuals with ELF ≥9.8 are considered at high risk of having MASH with advanced liver fibrosis (≥F3–F4) and therefore are at risk for adverse liver outcomes”
> “An ELF <9.8 suggests an individual is at low risk of advanced liver fibrosis and may be followed in the nonspecialty clinic with repeat testing in ≥2 years but may need repeat testing more often if ELF is between 9.2 and 9.7.”

Source: [American Diabetes Association Professional Practice Committee (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12690184/)

<a id="topic-2.2.1.5-13"></a>

### Enhanced Liver Fibrosis test: thresholds, AASLD 2023 practice guidance

> “The ELF panel is a proprietary blood test consisting of three elements involved in matrix turnover: hyaluronic acid, tissue inhibitor of metalloproteinase-1, and N-terminal procollagen III peptide. An ELF score of ≥ 9.8 reliably identifies patients with NAFLD at increased risk of progression to cirrhosis and liver-related clinical events.”
> “Note that in patients with confirmed or suspected advanced fibrosis, an ELF ≥ 11.3 is a predictor of future liver-related events and is approved for this purpose; use of other ELF cutoffs in secondary risk assessment is based on expert option.”

Source: [Rinella et al. (2023a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10735173/)

<a id="topic-2.2.1.5-14"></a>

### Magnetic resonance elastography: accuracy and thresholds, AASLD 2023 practice guidance

> “MRE is more sensitive than VCTE in the detection of fibrosis stage ≥ 2”
> “Although MRE is not a first-line approach to risk stratification in a patient with NAFLD, it can be an important tool if clinical uncertainty exists, if there is a need for concomitant cross-sectional imaging, or when other elastography techniques are unavailable.”
> “An LSM by MRE ≥ 5 kPa is suggestive of cirrhosis”
> “Note that the units for LSM by VCTE and MRE are both kilopascals, but the scales are different.”

Source: [Rinella et al. (2023a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10735173/)

<a id="topic-2.2.1.5-15"></a>

### Rule-out and rule-in cut-offs of non-invasive tests for fibrosis and at-risk MASH, EASL-EASD-EASO 2024 guideline

| Non-invasive test | Rule-out cut-off | Rule-in cut-off |
| --- | --- | --- |
| FIB-4 | “F3: 1.3” | “F3: 2.67” |
| ELF | “F3: 7.7” | “F3: 9.8” |
| VCTE liver stiffness | “F3: 8 kPa” | “F3: 12 kPa” |
| MEFIB (MRE combined with FIB-4) | “F2: MRE <3.3 kPa and FIB-4 <1.6” | “F2: MRE ≥3.3 kPa and FIB-4 ≥1.6” |

Source: [European Association for the Study of the Liver (2024)](https://www.journal-of-hepatology.eu/article/S0168-8278%2824%2900329-5/fulltext)

<a id="topic-2.2.1.5-16"></a>

### FibroScan-AST score for at-risk NASH: rule-out and rule-in cut-offs

> “The most predictive model combined LSM, CAP, and AST, and was designated FAST (FibroScan-AST).”
> “Cutoff for sensitivity (≥0·90) was 0·35 and for specificity (≥0·90) was 0·67 in the derivation cohort”

Source: [Newsome et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7066580/)

<a id="topic-2.2.1.5-17"></a>

### Selection of resmetirom candidates with non-invasive tests: AASLD 2024 guidance update

> “There are no FDA-approved noninvasive tests to diagnose MASH with F2-F3 or to monitor response to pharmacotherapy.”
> “Notably, the FDA-approved label does not require liver biopsy to confirm the diagnosis of fibrotic MASH. While MASH can only be definitively diagnosed by histologic examination, patient selection in practice is based on evidence of steatosis and fibrosis as determined by NILDA methodologies among persons with cardiometabolic risk factors without other causes of steatosis, notably alcohol consumption of more than 20 g/d for women and more than 30 g/d for men.”
> “In general, imaging-based NILDAs, such as liver stiffness measurement (LSM) by vibration-controlled transient elastography (VCTE) or magnetic resonance elastography (MRE),”
> “In the MAESTRO-NASH trial, participants were screened with VCTE and those with LSM >8.5 kPa in whom liver histology demonstrated MASH with F2-F3 were enrolled. Among enrolled participants, the median (interquartile range) LSM by VCTE was 12 kPa (10-15 kPa) and the mean LSM by MRE was 3.5 kPa. The median (interquartile range) of the enhanced liver fibrosis score was 9.7 (9.2-10.4).”
> “For example, 50% of participants with biopsy-proven F2-F3 in the MAESTRO-NASH trial had LSM by VCTE that was outside the interquartile range of 10 kPa to 15 kPa.”

Source: [Chen et al. (2025)](https://journals.lww.com/hep/fulltext/10.1097/hep.0000000000001112~resmetirom-therapy-for-metabolic-dysfunction-associated)

<a id="topic-2.2.1.5-18"></a>

### Selection of semaglutide candidates with non-invasive tests: AASLD 2025 guidance update

> “Semaglutide (Wegovy) candidates should have MASH with stages 2–3 fibrosis, identified using non-invasive tests (NITs) such as VCTE (8–15 kPa), MRE (3.1–4.4 kPa), or ELF (9.2–10.5), rather than liver biopsy, which is impractical and unnecessary for most patients. In those with VCTE (15–20 kPa), MRE (4.4–5 kPa), or ELF (10.5–11.3), an individualized decision to treat should be based on exclusion of cirrhosis with another confirmatory NIT, or cross-sectional imaging excluding nodular-appearing liver contour and signs of portal hypertension, or a platelet count of <150,000/mm3.”
> “Semaglutide is not approved as an indication for patients with MASH cirrhosis (VCTE >20 kPa, MRE >5.0 kPa, ELF >11.3, and/or evidence of portal hypertension).”
> “A FIB-4 score below 1.3 excludes advanced fibrosis (F3 or greater) in 99% of all patients and 95% of patients with multiple cardiometabolic risks in the primary care setting.”
> “To be clear, FIB-4 should not be used as a single rule-in or rule-out test for semaglutide eligibility for patients with MASLD/MASH.”
> “The recommended range of 8–15 kPa included ~50% of the study population, while up to 19% of participants had LSM <8 kPa, and up to 32.5% of participants had LSM ≥15 kPa.”

Source: [Bansal et al. (2026)](https://journals.lww.com/hep/fulltext/10.1097/hep.0000000000001608~semaglutide-therapy-for-metabolic-dysfunctionassociated)

<a id="topic-2.2.1.5-19"></a>

### Diagnosis rate of noncirrhotic NASH with moderate to advanced fibrosis: US population calculator for resmetirom eligibility

> “Published analyses suggest a diagnosis rate of ~ 10% (range 3.3–14.3%) and ~ 16% year-over-year growth in the treatment-eligible population.”
> “Estimation of the treatment-eligible population for resmetirom depends importantly on NASH diagnosis rates, which are predicted to be < 15% in the 3 years after drug approval.”
> “First, from additional analysis of NHANES data, it is estimated that 14.3% of prevalent patients with F2/F3 NASH have received a diagnosis of liver disease in a clinical setting (based on survey responses)”

Source: [Fishman et al. (2024b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11480167/)

<a id="topic-2.2.1.5-20"></a>

### Prevalence of diagnosed NASH: US adults, National Health and Wellness Survey 2016

> “Data came from the 2016 National Health and Wellness Survey, a nationally representative patient-reported outcomes survey conducted in the United States.”
> “The 2016 prevalence of diagnosed NASH among the US adult population was 0.15%.”

Source: [Tapper et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10077759/)

<a id="topic-2.2.1.5-21"></a>

### Self-reported liver disease awareness: US adults with MASLD and with liver stiffness 8 to 15 kPa, NHANES 2017 to 2023

> “This study utilized the NHANES data cycle 2017–2020 and 2021–2023, a nationally representative survey of the noninstitutionalized U.S. population conducted by the National Center for Health Statistics (NCHS), which included vibration-controlled transient elastography (VCTE) data.”
> “Individuals with MASLD and LS 8–15 kPa were considered resmetirom-eligible in this study.”
> “Awareness of liver disease among individuals with MASLD remained low, with 5.8% (95% CI: 4.5%–7.2%) pre-pandemic and 6.7% (95% CI: 5.4%–8.1%) late-pandemic reporting awareness (p=0.36). Among those eligible for resmetirom, awareness was 12.1% (95% CI: 5.4%–18.8%) pre-pandemic and 10.3% (95% CI: 6.4%–14.2%) late-pandemic (p=0.63).”

Source: [Alp et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12520227/)

<a id="topic-2.2.1.5-22"></a>

### Underdiagnosis of at-risk MASH in type 2 diabetes or prediabetes

> “Clinicians underestimate the prevalence of at-risk MASH and do not consistently implement appropriate screening strategies in people with prediabetes or type 2 diabetes, thus missing a chance to establish an early diagnosis. This pattern of underdiagnosis is compounded by sparse referral to specialists and inadequate prescription of medications with potential efficacy in MASH”

Source: [American Diabetes Association Professional Practice Committee (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12690184/)

Additional sources: [Sterling et al. (2025a)](https://pubmed.ncbi.nlm.nih.gov/38489523/); [Sterling et al. (2025b)](https://pubmed.ncbi.nlm.nih.gov/38489518/); [Cusi et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/35569886/)

## Related pages
- [Lanifibranor (IVA337): Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Terms and abbreviations](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/terms-and-abbreviations.md)
- [Lanifibranor (IVA337): Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/executive-summary.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Product information and disease description](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/product-information-and-disease-description.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Clinical evidence](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/clinical-evidence.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Economic information and modeling report](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/economics) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/economics.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: References](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/references) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/references.md)
